[
  {
    "ts": null,
    "headline": "Top 15 High-Growth Dividend Stocks For July 2025",
    "summary": "The Top 15 High-Growth Dividend Stocks for July 2025 boast a 1.38% yield, 18.78% growth rate and 23% undervaluation. Read more analysis here.",
    "url": "https://finnhub.io/api/news?id=db68923c43750f711ee4eb0686c20e0ef46577dda3b952452564eada3f9f2da7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751403721,
      "headline": "Top 15 High-Growth Dividend Stocks For July 2025",
      "id": 135700685,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160360708/image_2160360708.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Top 15 High-Growth Dividend Stocks for July 2025 boast a 1.38% yield, 18.78% growth rate and 23% undervaluation. Read more analysis here.",
      "url": "https://finnhub.io/api/news?id=db68923c43750f711ee4eb0686c20e0ef46577dda3b952452564eada3f9f2da7"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch",
    "summary": "(Updates with Novo Nordisk response in the last paragraph.) Novo Nordisk (NVO)'s top executives d",
    "url": "https://finnhub.io/api/news?id=a194436cca04e3c4bf6ee1347c32fde8c70e7559aa02bac1aadcdbf8c6c33771",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751378957,
      "headline": "Update: Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch",
      "id": 135693884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with Novo Nordisk response in the last paragraph.) Novo Nordisk (NVO)'s top executives d",
      "url": "https://finnhub.io/api/news?id=a194436cca04e3c4bf6ee1347c32fde8c70e7559aa02bac1aadcdbf8c6c33771"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=75012b038c5702fd0d0097bef12cccbab586d5f7ac218695b169537ff31d9a73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751374806,
      "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
      "id": 135693885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=75012b038c5702fd0d0097bef12cccbab586d5f7ac218695b169537ff31d9a73"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever",
    "summary": "Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever",
    "url": "https://finnhub.io/api/news?id=022b368da4e72d3ca702740f262bb7d4c2c21e18ff06bb44792224496f1f3016",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751373049,
      "headline": "Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever",
      "id": 135693591,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=022b368da4e72d3ca702740f262bb7d4c2c21e18ff06bb44792224496f1f3016"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch",
    "summary": "Novo Nordisk (NVO)'s top executives did not heed internal warnings that the company was not fully pr",
    "url": "https://finnhub.io/api/news?id=eddce8931463d73780954b3fedbd0c0eeffc8c4b74d5c5b19827b8cac1229a13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751372150,
      "headline": "Market Chatter: Novo Nordisk Executives Ignored Warnings Against Wegovy Launch",
      "id": 135692400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO)'s top executives did not heed internal warnings that the company was not fully pr",
      "url": "https://finnhub.io/api/news?id=eddce8931463d73780954b3fedbd0c0eeffc8c4b74d5c5b19827b8cac1229a13"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?",
    "summary": "Sector ETF report for IHE",
    "url": "https://finnhub.io/api/news?id=4e28bd1a7cc07dd3a226662596ba23d4c0314a0db01a1800587eee6dccc2f9fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365206,
      "headline": "Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?",
      "id": 135692453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sector ETF report for IHE",
      "url": "https://finnhub.io/api/news?id=4e28bd1a7cc07dd3a226662596ba23d4c0314a0db01a1800587eee6dccc2f9fb"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
    "summary": "Sector ETF report for FHLC",
    "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751365206,
      "headline": "Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?",
      "id": 135693887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sector ETF report for FHLC",
      "url": "https://finnhub.io/api/news?id=2bb96508dd28b29f360489c0f4247aefc4d31170870fba8c025ac3c486b232c3"
    }
  },
  {
    "ts": null,
    "headline": "How Novo Nordisk misread the US market for its weight loss sensation",
    "summary": "COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters.  Novo has enjoyed a tremendous windfall of $46 billion (292 billion Danish crowns) in net profit since mid-2021, when Wegovy became the first highly effective obesity treatment approved in the United States.  In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard Jorgensen.",
    "url": "https://finnhub.io/api/news?id=6ce3af809946960d6dc44c55935d9c5b1e682ed60cf1cec7a2e6502c1e049375",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751364409,
      "headline": "How Novo Nordisk misread the US market for its weight loss sensation",
      "id": 135692401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters.  Novo has enjoyed a tremendous windfall of $46 billion (292 billion Danish crowns) in net profit since mid-2021, when Wegovy became the first highly effective obesity treatment approved in the United States.  In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard Jorgensen.",
      "url": "https://finnhub.io/api/news?id=6ce3af809946960d6dc44c55935d9c5b1e682ed60cf1cec7a2e6502c1e049375"
    }
  },
  {
    "ts": null,
    "headline": "China's Innogen expects to complete weight-loss drug trials next year",
    "summary": "Chinese drugmaker Innogenexpects to complete a late-stage clinical trial of itsexperimental weight-loss drug candidate next year, its CEO saidon Tuesday, the latest Chinese company to join the race...",
    "url": "https://finnhub.io/api/news?id=a3d55367db5cece9729d7fa92d43c9e87173ec795770a558f13900f1a7303a3c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751364147,
      "headline": "China's Innogen expects to complete weight-loss drug trials next year",
      "id": 135692506,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Chinese drugmaker Innogenexpects to complete a late-stage clinical trial of itsexperimental weight-loss drug candidate next year, its CEO saidon Tuesday, the latest Chinese company to join the race...",
      "url": "https://finnhub.io/api/news?id=a3d55367db5cece9729d7fa92d43c9e87173ec795770a558f13900f1a7303a3c"
    }
  }
]